Saturday 17 October 2026
Export KALA’s income statement to Excel — free account
KALA BIO, Inc.
KALA Healthcare Biotechnology
KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million. In the quarter to June 2026, EPS grew 75.1% and free cash flow grew 80.2%, each against the same quarter a year earlier.
0.19
0.00
0.00%
Follow KALA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
4.70 | 5.63 | 3.03 | 0.65 | |
Current Ratio |
6.88 | 7.91 | 3.81 | 0.75 | |
Net Debt/EBITDA |
4.20 | 4.86 | 0.67 | (1.05) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 113.55% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | (3.28) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.97 | 1.79 | (6.64) | 1.44 | |
Capex/Depreciation |
— | — | 0.00 | (0.06) | |
Interest Coverage |
— | — | (72.52) | (7.52) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(20.69) | (0.24) | (27.95) | (77.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.11) | |
Free Cash Flow per Share |
(20.69) | (0.24) | (27.95) | (77.36) | |
Cash per Share |
97.43 | 0.74 | 46.36 | 149.83 | |
Shareholders Equity per Share |
121.89 | 0.91 | 42.92 | (61.54) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
121.89 | 0.91 | 42.92 | (61.54) | |
Free Cash Flow |
(1.53) | (2.89) | (4.56) | (10.89) | |
Working Capital |
9.04 | 10.76 | 7.00 | (8.30) | |
Capital Expenditures |
— | — | 0.00 | (0.01) | |
Net Current Asset Value |
9.04 | 10.76 | 7.00 | (9.41) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.90 | 0.99 | 0.81 | 0.81 | |
Average Assets |
23.32 | 30.29 | 32.49 | 39.55 | |
Average Common Equity |
2.92 | 8.23 | 9.66 | (0.90) |
Columns are period end dates